108 related articles for article (PubMed ID: 17381421)
1. Functional PET imaging in cancer drug development.
Avril N; Propper D
Future Oncol; 2007 Apr; 3(2):215-28. PubMed ID: 17381421
[TBL] [Abstract][Full Text] [Related]
2. Monitoring response to treatment in patients utilizing PET.
Avril NE; Weber WA
Radiol Clin North Am; 2005 Jan; 43(1):189-204. PubMed ID: 15693656
[TBL] [Abstract][Full Text] [Related]
3. Use of PET for monitoring cancer therapy and for predicting outcome.
Weber WA
J Nucl Med; 2005 Jun; 46(6):983-95. PubMed ID: 15937310
[TBL] [Abstract][Full Text] [Related]
4. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
5. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
Kelloff GJ; Hoffman JM; Johnson B; Scher HI; Siegel BA; Cheng EY; Cheson BD; O'shaughnessy J; Guyton KZ; Mankoff DA; Shankar L; Larson SM; Sigman CC; Schilsky RL; Sullivan DC
Clin Cancer Res; 2005 Apr; 11(8):2785-808. PubMed ID: 15837727
[TBL] [Abstract][Full Text] [Related]
6. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
7. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
8. PET in anti-cancer drug development and therapy.
Kumar R; Lal N
Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):259-63. PubMed ID: 18221070
[TBL] [Abstract][Full Text] [Related]
9. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
10. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine.
Salskov A; Tammisetti VS; Grierson J; Vesselle H
Semin Nucl Med; 2007 Nov; 37(6):429-39. PubMed ID: 17920350
[TBL] [Abstract][Full Text] [Related]
11. Neuronuclear assessment of patients with epilepsy.
Goffin K; Dedeurwaerdere S; Van Laere K; Van Paesschen W
Semin Nucl Med; 2008 Jul; 38(4):227-39. PubMed ID: 18514079
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography as an imaging biomarker.
Weber WA
J Clin Oncol; 2006 Jul; 24(20):3282-92. PubMed ID: 16829652
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.
Mankoff DA; Eary JF; Link JM; Muzi M; Rajendran JG; Spence AM; Krohn KA
Clin Cancer Res; 2007 Jun; 13(12):3460-9. PubMed ID: 17575208
[TBL] [Abstract][Full Text] [Related]
16. Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.
Jacobson O; Chen X
Pharmacol Rev; 2013; 65(4):1214-56. PubMed ID: 24064460
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
18. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
[TBL] [Abstract][Full Text] [Related]
19. Functional imaging for early prediction of response to chemoradiotherapy: 3'-deoxy-3'-18F-fluorothymidine positron emission tomography--a clinical application model of esophageal cancer.
Chao KS
Semin Oncol; 2006 Dec; 33(6 Suppl 11):S59-63. PubMed ID: 17178290
[TBL] [Abstract][Full Text] [Related]
20. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
